Lichen China raises $3.5M as shares plunge 70%
What's the deal? Lichen ChinaDealroom has a profile for this one. Try Dealroom → (NASDAQ: LICN), a China-based financial and taxation services provider, priced a $3.5 million registered direct offering with institutional investors. It is selling 17.5 million units at $0.20 each, with Univest SecuritiesDealroom has a profile for this one. Try Dealroom → as sole placement agent. The deal is set to close on November 11, 2026.
The structure: Each unit bundles one Class A ordinary share — or a pre-funded warrant — with a warrant to buy 4.72 more shares at $0.20, exercisable immediately and expiring in one year. That design is heavily dilutive, and the stock reacted sharply: LICN shares fell 70.5% in premarket trading.
Why now? The raise follows an $18.6 million private placement in September 2025, signalling continued reliance on equity financing. Lichen is under strain, having reported a wider first-half 2026 net loss and recently disposed of its loss-making BondlyDealroom has a profile for this one. Try Dealroom → subsidiary for US$0.12.
What could go wrong? The company is seeking another share consolidation to meet Nasdaq's minimum-bid requirement after a prior reverse split. If the warrants are exercised, Lichen gains more cash but existing holders face substantial further dilution.
The signal: The round matters less for its size than for what it reveals — a small-cap issuer leaning repeatedly on dilutive equity to stay funded and listed. For investors, the structure, not the headline figure, tells the story.
Read more: Business Insider
Image credit: Generated with Gemini